1,590,000 Shares in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Bought by Boxer Capital Management LLC

Boxer Capital Management LLC bought a new position in shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV - Free Report) in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 1,590,000 shares of the specialty pharmaceutical company's stock, valued at approximately $13,467,000. KalVista Pharmaceuticals accounts for about 1.1% of Boxer Capital Management LLC's holdings, making the stock its 27th biggest holding. Boxer Capital Management LLC owned 3.22% of KalVista Pharmaceuticals as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in the stock. Aquatic Capital Management LLC purchased a new position in shares of KalVista Pharmaceuticals during the fourth quarter worth $44,000. Tower Research Capital LLC TRC grew its stake in KalVista Pharmaceuticals by 666.9% during the 4th quarter. Tower Research Capital LLC TRC now owns 6,327 shares of the specialty pharmaceutical company's stock worth $54,000 after purchasing an additional 5,502 shares in the last quarter. Legal & General Group Plc boosted its stake in shares of KalVista Pharmaceuticals by 22.5% in the 4th quarter. Legal & General Group Plc now owns 8,144 shares of the specialty pharmaceutical company's stock valued at $69,000 after buying an additional 1,494 shares during the period. Martin Worley Group acquired a new position in shares of KalVista Pharmaceuticals during the fourth quarter worth about $86,000. Finally, China Universal Asset Management Co. Ltd. raised its holdings in KalVista Pharmaceuticals by 24.7% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 10,329 shares of the specialty pharmaceutical company's stock valued at $87,000 after acquiring an additional 2,043 shares in the last quarter.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently weighed in on the company. Citizens Jmp raised KalVista Pharmaceuticals to a "strong-buy" rating in a research report on Friday, January 31st. HC Wainwright restated a "buy" rating and set a $20.00 price objective on shares of KalVista Pharmaceuticals in a research report on Friday, March 14th. JMP Securities began coverage on KalVista Pharmaceuticals in a report on Friday, January 31st. They issued an "outperform" rating and a $19.00 target price for the company. TD Cowen initiated coverage on KalVista Pharmaceuticals in a research report on Tuesday, January 7th. They set a "buy" rating and a $30.00 price objective for the company. Finally, Needham & Company LLC reaffirmed a "buy" rating and set a $28.00 price objective on shares of KalVista Pharmaceuticals in a research note on Tuesday, April 8th. Seven equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat, the stock presently has a consensus rating of "Buy" and a consensus price target of $24.83.

KalVista Pharmaceuticals Trading Down 0.4 %

NASDAQ KALV traded down $0.05 during trading on Wednesday, reaching $12.44. 72,066 shares of the company's stock were exchanged, compared to its average volume of 411,450. The firm has a market capitalization of $618.47 million, a PE ratio of -3.43 and a beta of 0.05. The company's fifty day simple moving average is $11.99 and its 200-day simple moving average is $10.42. KalVista Pharmaceuticals, Inc. has a fifty-two week low of $7.30 and a fifty-two week high of $15.50.

Insider Buying and Selling at KalVista Pharmaceuticals

In related news, CEO Benjamin L. Palleiko sold 6,669 shares of the company's stock in a transaction on Friday, March 7th. The shares were sold at an average price of $11.97, for a total transaction of $79,827.93. Following the completion of the transaction, the chief executive officer now directly owns 287,811 shares in the company, valued at $3,445,097.67. This represents a 2.26 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Paul K. Audhya sold 3,125 shares of the firm's stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $9.82, for a total value of $30,687.50. Following the completion of the transaction, the insider now directly owns 100,334 shares of the company's stock, valued at approximately $985,279.88. This trade represents a 3.02 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have purchased 202,786 shares of company stock worth $1,880,511 and have sold 17,292 shares worth $184,625. Corporate insiders own 10.50% of the company's stock.

KalVista Pharmaceuticals Company Profile

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company's product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).